These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

370 related items for PubMed ID: 18498916

  • 1. Current target ranges of mycophenolic acid exposure and drug-related adverse events: a 5-year, open-label, prospective, clinical follow-up study in renal allograft recipients.
    Kuypers DR, de Jonge H, Naesens M, de Loor H, Halewijck E, Dekens M, Vanrenterghem Y.
    Clin Ther; 2008 Apr; 30(4):673-83. PubMed ID: 18498916
    [Abstract] [Full Text] [Related]

  • 2. The impact of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T on early mycophenolic acid dose-interval exposure in de novo renal allograft recipients.
    Kuypers DR, Naesens M, Vermeire S, Vanrenterghem Y.
    Clin Pharmacol Ther; 2005 Oct; 78(4):351-61. PubMed ID: 16198654
    [Abstract] [Full Text] [Related]

  • 3. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
    Dösch AO, Ehlermann P, Koch A, Remppis A, Katus HA, Dengler TJ.
    Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
    [Abstract] [Full Text] [Related]

  • 4. UGT1A9 -275T>A/-2152C>T polymorphisms correlate with low MPA exposure and acute rejection in MMF/tacrolimus-treated kidney transplant patients.
    van Schaik RH, van Agteren M, de Fijter JW, Hartmann A, Schmidt J, Budde K, Kuypers D, Le Meur Y, van der Werf M, Mamelok R, van Gelder T.
    Clin Pharmacol Ther; 2009 Sep; 86(3):319-27. PubMed ID: 19494809
    [Abstract] [Full Text] [Related]

  • 5. C-440T/T-331C polymorphisms in the UGT1A9 gene affect the pharmacokinetics of mycophenolic acid in kidney transplantation.
    Baldelli S, Merlini S, Perico N, Nicastri A, Cortinovis M, Gotti E, Remuzzi G, Cattaneo D.
    Pharmacogenomics; 2007 Sep; 8(9):1127-41. PubMed ID: 17924828
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Rifampin induces alterations in mycophenolic acid glucuronidation and elimination: implications for drug exposure in renal allograft recipients.
    Naesens M, Kuypers DR, Streit F, Armstrong VW, Oellerich M, Verbeke K, Vanrenterghem Y.
    Clin Pharmacol Ther; 2006 Nov; 80(5):509-21. PubMed ID: 17112807
    [Abstract] [Full Text] [Related]

  • 8. Clinical efficacy and toxicity profile of tacrolimus and mycophenolic acid in relation to combined long-term pharmacokinetics in de novo renal allograft recipients.
    Kuypers DR, Claes K, Evenepoel P, Maes B, Vanrenterghem Y.
    Clin Pharmacol Ther; 2004 May; 75(5):434-47. PubMed ID: 15116056
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Mycophenolate, clinical pharmacokinetics, formulations, and methods for assessing drug exposure.
    Tett SE, Saint-Marcoux F, Staatz CE, Brunet M, Vinks AA, Miura M, Marquet P, Kuypers DR, van Gelder T, Cattaneo D.
    Transplant Rev (Orlando); 2011 Apr; 25(2):47-57. PubMed ID: 21190834
    [Abstract] [Full Text] [Related]

  • 13. Comparison of pharmacokinetics of mycophenolic acid and its metabolites between living donor liver transplant recipients and deceased donor liver transplant recipients.
    Shen B, Chen B, Zhang W, Mao H, Shen C, Deng X, Zhan X, Chen H.
    Liver Transpl; 2009 Nov; 15(11):1473-80. PubMed ID: 19877254
    [Abstract] [Full Text] [Related]

  • 14. Mycophenolic acid 12-hour area under the curve in de novo liver transplant patients given mycophenolate mofetil at fixed versus concentration-controlled doses.
    Kamar N, Marquet P, Gandia P, Muscari F, Lavayssière L, Esposito L, Guitard J, Canivet C, Peron JM, Alric L, Suc B, Saint-Marcoux F, Rostaing L.
    Ther Drug Monit; 2009 Aug; 31(4):451-6. PubMed ID: 19531983
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Monitoring mycophenolic acid pharmacokinetic parameters in liver transplant recipients: prediction of occurrence of leukopenia.
    Hao C, Anwei M, Bing C, Baiyong S, Weixia Z, Chuan S, Erzhen C, Xiaxing D, Weihua Q, Weiping Y, Chenghong P, Hongwei L.
    Liver Transpl; 2008 Aug; 14(8):1165-73. PubMed ID: 18668650
    [Abstract] [Full Text] [Related]

  • 17. Limits to intensified mycophenolate mofetil dosing in kidney transplantation.
    Kiberd BA, Lawen J, Daley C.
    Ther Drug Monit; 2012 Dec; 34(6):736-8. PubMed ID: 23007746
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients.
    Staatz CE, Tett SE.
    Clin Pharmacokinet; 2007 Dec; 46(1):13-58. PubMed ID: 17201457
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.